-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Financial App News, and Platinum Pharmaceutical-B (02142.HK) announced that the China National Drug Administration (China Drug Administration) has accepted the company's first new drug clinical trial (IND) application for the next-generation targeted ACVR2A/2B monoclonal antibody LET003 developed using the HU-Matrix™ AI platform to treat overweight or obesity. LET003 is a potentially best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating the homeostasis of muscle-fat metabolism.
Share
Listen to the news
Zhitong Financial App News, and Platinum Pharmaceutical-B (02142.HK) announced that the China National Drug Administration (China Drug Administration) has accepted the company's first new drug clinical trial (IND) application for the next-generation targeted ACVR2A/2B monoclonal antibody LET003 developed using the HU-Matrix™ AI platform to treat overweight or obesity. LET003 is a potentially best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating the homeostasis of muscle-fat metabolism.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending